Eagle Pharmaceuticals Inc. (EGRX)

81.98
NASDAQ : Health Technology
Prev Close 81.98
Day Low/High 0.00 / 0.00
52 Wk Low/High 45.05 / 83.50
Avg Volume 232.50K
Exchange NASDAQ
Shares Outstanding 14.86M
Market Cap 1.19B
EPS 3.40
P/E Ratio 39.52
Div & Yield N.A. (N.A)

Latest News

Court Issues Decision In Favor Of Eagle Pharmaceuticals Granting Seven Year Orphan Drug Exclusivity For BENDEKA (bendamustine Hydrochloride Injection)

Court Issues Decision In Favor Of Eagle Pharmaceuticals Granting Seven Year Orphan Drug Exclusivity For BENDEKA (bendamustine Hydrochloride Injection)

Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) ("Eagle" or the "Company") announced today that the U.

Eagle Pharmaceuticals, Inc. Granted Final FDA Approval For Bendamustine Hydrochloride Ready-to-Dilute Solution In A 500ml Admixture

Eagle Pharmaceuticals, Inc. Granted Final FDA Approval For Bendamustine Hydrochloride Ready-to-Dilute Solution In A 500ml Admixture

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (Nasdaq:EGRX) today announced that the U.

EGRX Crosses Above Average Analyst Target

In recent trading, shares of Eagle Pharmaceuticals, Inc. have crossed above the average analyst 12-month target price of $64.33, changing hands for $65.57/share.

Eagle Pharmaceuticals, Inc. Reports First Quarter 2018 Results

Eagle Pharmaceuticals, Inc. Reports First Quarter 2018 Results

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (Nasdaq: EGRX) today announced its financial results for the three months ended March 31, 2018.

EGRX Crosses Above Key Moving Average Level

In trading on Monday, shares of Eagle Pharmaceuticals, Inc. crossed above their 200 day moving average of $56.30, changing hands as high as $58.25 per share.

Eagle Pharmaceuticals, Inc. To Discuss First Quarter 2018 Financial Results On May 10, 2018

Eagle Pharmaceuticals, Inc. To Discuss First Quarter 2018 Financial Results On May 10, 2018

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (Nasdaq: EGRX) today announced that the Company will release its 2018 first quarter financial results on Thursday, May 10, 2018, before the market opens.

Eagle Pharmaceuticals, Inc. To Present At 43rd Annual Deutsche Bank Health Care Conference

Eagle Pharmaceuticals, Inc. To Present At 43rd Annual Deutsche Bank Health Care Conference

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) announced today that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 43rd Annual Deutsche Bank Health Care Conference as follows:   ...

Three Biotech Names to Consider

Three Biotech Names to Consider

A look at three names to consider in the biotech and biopharma space.

Eagle Pharmaceuticals Announces New Patent For Eagle Biologics

Eagle Pharmaceuticals Announces New Patent For Eagle Biologics

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or "the Company") today announced that the Company's Eagle Biologics division has been issued a new patent by the United States Patent and Trademark Office (USPTO).

Eagle Pharmaceuticals, Inc. Reports Fourth Quarter And Full Year 2017 Results

Eagle Pharmaceuticals, Inc. Reports Fourth Quarter And Full Year 2017 Results

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (Nasdaq: EGRX) today announced its financial results for the three- and twelve-months ended December 31, 2017.

Eagle Pharmaceuticals, Inc. To Discuss Fourth Quarter And Year End 2017 Financial Results On February 26, 2018

Eagle Pharmaceuticals, Inc. To Discuss Fourth Quarter And Year End 2017 Financial Results On February 26, 2018

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (Nasdaq: EGRX) today announced that the Company will release its 2017 fourth quarter and full year financial results on Monday, February 26, 2018, before the market...

EGRX Crosses Above Key Moving Average Level

EGRX Crosses Above Key Moving Average Level

In trading on Thursday, shares of Eagle Pharmaceuticals, Inc. crossed above their 200 day moving average of $62.84, changing hands as high as $63.52 per share.

Eagle Pharmaceuticals, Inc. To Present At 2018 RBC Capital Markets Global Healthcare Conference

Eagle Pharmaceuticals, Inc. To Present At 2018 RBC Capital Markets Global Healthcare Conference

Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) ("Eagle" or "the Company") today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 2018 RBC Capital Markets Global...

Eagle Pharmaceuticals Announces Fifth Orange Book Listed Patent For RYANODEX

Eagle Pharmaceuticals Announces Fifth Orange Book Listed Patent For RYANODEX

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or "the Company") today announced that the Company has been issued a new patent related to its RYANODEX ® product (dantrolene sodium for injectable suspension) by the...

Eagle Pharmaceuticals Reaches Analyst Target Price

Eagle Pharmaceuticals Reaches Analyst Target Price

In recent trading, shares of Eagle Pharmaceuticals, Inc. have crossed above the average analyst 12-month target price of $62.33, changing hands for $62.56/share.

Eagle Pharmaceuticals, Inc. To Present At 36th Annual J.P. Morgan Healthcare Conference

Eagle Pharmaceuticals, Inc. To Present At 36th Annual J.P. Morgan Healthcare Conference

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or "the Company") today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 36th Annual J.

EGRX: Insiders vs. Shorts

EGRX: Insiders vs. Shorts

The most recent short interest data was recently released for the 11/30/2017 settlement date, and Eagle Pharmaceuticals, Inc. is one of the most shorted stocks of the Russell 3000, based on 18.70 "days to cover" versus the median component at 5.11.

PayPal, Skyworks Solutions, Cisco Systems: 'Mad Money' Lightning Round

PayPal, Skyworks Solutions, Cisco Systems: 'Mad Money' Lightning Round

Jim Cramer makes a call on PayPal, Skyworks Solutions, Cisco Systems, Frontier Communications and more.

Get Your Game Plan Ready: Cramer's 'Mad Money' Recap (Friday 12/15/17)

Get Your Game Plan Ready: Cramer's 'Mad Money' Recap (Friday 12/15/17)

Earnings are still in charge of this bull, says Jim Cramer. You can't keep good market down.

Eagle Pharmaceuticals Commences Pivotal Study For Fulvestrant

Eagle Pharmaceuticals Commences Pivotal Study For Fulvestrant

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or "the Company") today announced that it has begun dosing subjects in its pivotal study for the Company's fulvestrant formulation intended as a monotherapy treatment of...

Eagle Pharmaceuticals, Inc. To Present At 29th Annual Piper Jaffray Healthcare Conference

Eagle Pharmaceuticals, Inc. To Present At 29th Annual Piper Jaffray Healthcare Conference

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or "the Company") today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 29th Annual Piper Jaffray...

Eagle Pharmaceuticals, Inc. Reports Third Quarter 2017 Results

Eagle Pharmaceuticals, Inc. Reports Third Quarter 2017 Results

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (Nasdaq: EGRX) today announced its financial results for the three- and nine-months ended September 30, 2017.

Eagle Pharmaceuticals, Inc. To Present At Jefferies 2017 London Healthcare Conference

Eagle Pharmaceuticals, Inc. To Present At Jefferies 2017 London Healthcare Conference

Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) ("Eagle" or "the Company") today announced that Scott Tarriff, Chief Executive Officer, will present at the Jefferies 2017 London Healthcare Conferences as follows: ...

Eagle Pharmaceuticals, Inc. To Discuss Third Quarter 2017 Financial Results On November 8, 2017

Eagle Pharmaceuticals, Inc. To Discuss Third Quarter 2017 Financial Results On November 8, 2017

Eagle Pharmaceuticals, Inc. ("Eagle" or "the Company") (Nasdaq:EGRX) today announced that the Company will release its 2017 third quarter financial results on Wednesday, November 8, 2017, before the market opens.

Eagle Pharmaceuticals Receives Tentative FDA Approval For PEMFEXY (Pemetrexed Injection) Ready-to-Dilute

Eagle Pharmaceuticals Receives Tentative FDA Approval For PEMFEXY (Pemetrexed Injection) Ready-to-Dilute

Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) ("Eagle" or "the Company") today announced that the United States Food and Drug Administration ("FDA") has granted tentative approval for the Company's PEMFEXY™, a pemetrexed...

Eagle Pharmaceuticals Announces New Patent For RYANODEX

Eagle Pharmaceuticals Announces New Patent For RYANODEX

Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) ("Eagle" or "the Company") today announced that the Company has been issued a new patent related to its RYANODEX ® formulation (dantrolene sodium) by the United States Patent...

3 Biotech Values in a Fully Valued Market

3 Biotech Values in a Fully Valued Market

Eagle Pharmaceuticals, Aratana Therapeutics and Progenics Pharmaceuticals show promise.

TheStreet Quant Rating: C (Hold)